Trupanion, Inc. (NASDAQ:TRUP – Get Free Report) CFO Fawwad Qureshi sold 622 shares of the company’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $52.61, for a total transaction of $32,723.42. Following the transaction, the chief financial officer now owns 9,867 shares in the company, valued at approximately $519,102.87. This trade represents a 5.93 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Trupanion Trading Down 1.6 %
Shares of NASDAQ:TRUP traded down $0.85 during mid-day trading on Wednesday, reaching $53.50. The stock had a trading volume of 365,027 shares, compared to its average volume of 677,237. The firm has a market cap of $2.27 billion, a PE ratio of -167.19 and a beta of 1.69. The firm has a 50 day simple moving average of $49.50 and a two-hundred day simple moving average of $39.97. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.40. Trupanion, Inc. has a twelve month low of $19.69 and a twelve month high of $57.90.
Trupanion (NASDAQ:TRUP – Get Free Report) last posted its earnings results on Wednesday, October 30th. The financial services provider reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.09. Trupanion had a negative return on equity of 4.36% and a negative net margin of 1.08%. The business had revenue of $327.50 million during the quarter, compared to analysts’ expectations of $321.79 million. During the same period in the prior year, the business earned ($0.10) EPS. Trupanion’s revenue for the quarter was up 14.6% compared to the same quarter last year. On average, research analysts predict that Trupanion, Inc. will post -0.23 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Analysis on TRUP
Institutional Trading of Trupanion
A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in Trupanion by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 3,673,791 shares of the financial services provider’s stock worth $101,433,000 after purchasing an additional 32,485 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Trupanion by 4.4% during the 3rd quarter. Wellington Management Group LLP now owns 3,393,879 shares of the financial services provider’s stock worth $142,475,000 after acquiring an additional 142,156 shares in the last quarter. FMR LLC grew its stake in shares of Trupanion by 55,963.7% during the 3rd quarter. FMR LLC now owns 1,172,293 shares of the financial services provider’s stock worth $49,213,000 after acquiring an additional 1,170,202 shares in the last quarter. Marshall Wace LLP grew its stake in shares of Trupanion by 11.9% during the 2nd quarter. Marshall Wace LLP now owns 1,094,589 shares of the financial services provider’s stock worth $32,181,000 after acquiring an additional 116,496 shares in the last quarter. Finally, DF Dent & Co. Inc. grew its stake in shares of Trupanion by 27.8% during the 3rd quarter. DF Dent & Co. Inc. now owns 367,871 shares of the financial services provider’s stock worth $15,443,000 after acquiring an additional 80,014 shares in the last quarter.
Trupanion Company Profile
Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on a monthly subscription basis in the United States, Canada, Continental Europe, and Australia. The company operates in two segments, Subscription Business and Other Business. It serves pet owners and veterinarians.
Featured Articles
- Five stocks we like better than Trupanion
- What is a Low P/E Ratio and What Does it Tell Investors?
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Learn Technical Analysis Skills to Master the Stock Market
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- High Dividend REITs: Are They an Ideal Way to Diversify?
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Trupanion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion and related companies with MarketBeat.com's FREE daily email newsletter.